Soleno Therapeutics (SLNO) Revenue (2015 - 2026)

Soleno Therapeutics' (SLNO) quarterly Revenue came in at $94.6 million in Q1 2026, up 3.13% on a QoQ basis from $91.7 million in Q4 2025.

Soleno Therapeutics (SLNO) Revenue (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 5 years of Revenue data on file, last reported at $94.6 million in Q1 2026.

On a quarterly basis, Revenue changed N/A year-over-year to $94.6 million in Q1 2026; TTM through Mar 2026 was $285.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $190.4 million, changed N/A from the prior year.
Revenue for Q1 2026 stood at $94.6 million, up from $91.7 million in the prior quarter.
Over the last five years, Revenue for SLNO reached as high as $94.6 million in Q1 2026 and fell as low as $32.7 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	1.51 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	2.99 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	3.61 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	1.30 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Soleno Therapeutics	874.25 Mn	618.67 Mn	93.41 Mn	94.60 Mn

Download Data